Since December 2022, CDSCO and state regulators have conducted risk-based inspections at more than 960 drug manufacturing premises across India, highlighting the growing focus on GMP compliance. For companies across Delhi and NCR, pharma consultancy in Delhi can provide specialist support for CDSCO requirements, revised Schedule M, validation, quality systems, and inspection readiness. Moreover, expert pharma consultancy services help manufacturers identify compliance gaps, strengthen documentation, and prepare facilities for regulatory scrutiny. Therefore, the right technical support can reduce compliance risks and help pharmaceutical businesses build stronger, inspection-ready operations.
Table of Contents
What Does a Pharma Consultancy in Delhi Do?
A pharmaceutical consultancy in Delhi helps manufacturers, startups, and quality teams manage regulatory and technical requirements. Services may include GMP compliance, CDSCO support, licensing, audits, SOP development, validation, qualification, facility design, and inspection readiness. Consultants also identify compliance gaps and support CAPA, documentation, and quality system improvements. This helps pharmaceutical companies reduce regulatory risk, improve operational control, and move projects forward with greater confidence.
Why GMP and Regulatory Expertise Matters in Delhi?
Pharmaceutical companies in Delhi need more than general business advice. They need consultants who understand Schedule M, CDSCO expectations, GMP systems, and risk-based inspections. Moreover, specialists can connect regulatory requirements with practical controls on the manufacturing floor. This includes documentation, data integrity, validation, deviation management, and quality risk management. As a result, companies can close compliance gaps faster and prepare more effectively for inspections.
Which Compliance Areas Need Specialist Consultancy Before an Inspection?
Before an inspection, companies should focus on the areas most likely to expose compliance gaps. These include GMP documentation, data integrity, validation, deviation and CAPA systems, change control, training, and supplier oversight. In addition, consultants can review facility controls, equipment qualification, batch records, and audit readiness. As a result, teams can correct weaknesses early and present stronger evidence of ongoing compliance.
Key areas deserve particular attention before inspectors arrive, especially where documentation, control, and compliance evidence must work together.
- Revised Schedule M and GMP Gap Assessment (PDF Available)
- CDSCO Risk-Based Inspection Readiness (PDF Available)
- Pharmaceutical Quality Systems and CAPA Controls (PDF Available)
- Validation, Qualification and Facility Controls (PDF Available)
The infographic maps the four key pillars of Delhi pharmaceutical compliance Revised Schedule M, CDSCO readiness, quality systems, and validation to support stronger GMP inspection preparedness.
Revised Schedule M and GMP Gap Assessment (PDF)
Revised Schedule M strengthens GMP expectations for facilities, equipment, utilities, documentation, quality systems, and manufacturing controls. A structured gap assessment helps companies identify deficiencies and prioritize corrective actions before regulatory review.
Download Revised Schedule M GMP Compliance Extension – Form A Here
CDSCO Risk-Based Inspection Readiness (PDF)
CDSCO risk-based inspections focus on factors such as compliance history, product risk, manufacturing controls, and previous deficiencies. Companies should therefore maintain strong documentation, validated systems, effective CAPA, and clear evidence of ongoing GMP compliance.
Download Guidance Document for Risk Based Inspection of Drug Manufacturing Sites Here
Pharmaceutical Quality Systems and CAPA Controls (PDF)
ICH Q10 connects CAPA, change management, process monitoring, and management review within a lifecycle-based Pharmaceutical Quality System. Effective CAPA should identify root causes, control risks, and confirm that improvements remain effective over time.
Validation, Qualification and Facility Controls (PDF)
WHO guidance explains how qualification and validation demonstrate that facilities, utilities, equipment, systems, and processes perform as intended. Risk-based lifecycle controls such as DQ, IQ, OQ, and PQ help maintain consistent GMP performance.
Download Good manufacturing practices: guidelines on validation Here
How to Choose a Pharma Consultant in Delhi
Choose a pharma consultant in Delhi based on proven Schedule M, CDSCO, GMP, validation, and quality-system expertise. Also check relevant project experience, including audits, gap assessments, CAPA, and remediation work.
The table below shows the key capabilities to compare and the practical evidence you should request before selecting a pharmaceutical consultant.
| Area to Compare | What the Consultant Should Know | Evidence to Request |
|---|---|---|
|
Revised Schedule M |
Current GMP requirements for premises, equipment, utilities, documentation, personnel, and quality systems |
Schedule M gap assessments, remediation plans, or completed upgrade projects |
|
CDSCO Compliance |
Drugs Rules, licensing requirements, CDSCO expectations, and regulatory documentation |
Previous licensing, regulatory submission, or CDSCO compliance assignments |
|
GMP Inspection Readiness |
Risk-based inspections, deficiency classification, document review, and inspection preparation |
Mock-audit reports, inspection-readiness projects, and CAPA follow-up evidence |
|
Validation & Qualification |
Risk-based qualification and validation across equipment, utilities, processes, cleaning, and computerized systems |
Approved DQ, IQ, OQ, PQ, validation protocols, reports, or validation master plans |
|
Pharmaceutical Quality System |
CAPA, deviations, change control, complaints, management review, and continual improvement |
Quality-system assessments, CAPA remediation, SOP projects, or QMS implementation work |
|
Quality Risk Management |
Scientific risk assessment and risk-based decision-making within GMP operations |
FMEA, risk assessments, risk registers, or documented mitigation plans |
|
Facility & Utility Controls |
HVAC, water systems, material and personnel flows, contamination control, and facility qualification |
Facility design reviews, HVAC or water qualification projects, and GMP facility assessments |
|
Project Experience |
Practical implementation in pharmaceutical manufacturing, not only general management consulting |
References, anonymized case studies, project scope, deliverables, and measurable outcomes |
This infographic highlights eight practical checks for evaluating a pharma consultant in Delhi before engagement, helping companies reduce compliance risk and choose stronger GMP and regulatory support.
How a Pharma Consultancy Project Should Work
A well-managed pharma consultancy project starts with a detailed compliance assessment and clear gap analysis. Next, consultants prioritize risks based on product quality, patient safety, and regulatory impact. They then support remediation, documentation updates, validation, and staff training. In addition, mock inspections test whether systems and teams are ready for regulatory review. Finally, effectiveness checks confirm that corrective actions work and that improvements remain sustainable over time.
Final Words
India’s inspection environment is becoming more risk-based and enforcement-focused, with more than 860 regulatory actions taken following recent CDSCO and state inspections. Therefore, manufacturers should treat inspection readiness as an ongoing quality activity, not a last-minute exercise. The right pharma consultancy in Delhi can help strengthen GMP systems, close compliance gaps, and maintain sustainable regulatory readiness.
Qualification and Validation for GMP Systems
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
FAQ
Hire a consultant when you identify Schedule M gaps, recurring deviations, weak CAPA, incomplete validation, or poor inspection readiness. Early support gives teams time to correct deficiencies and verify effectiveness before regulators arrive.
A Schedule M gap assessment should review facilities, equipment, HVAC, utilities, documentation, technical staff, quality systems, and validation status. It should also rank gaps by risk and define clear remediation actions, owners, and timelines.
Companies should review critical systems, CAPA, deviations, data integrity, validation, training, and previous inspection findings. Mock inspections and evidence-based follow-up help confirm that controls are effective and inspection-ready.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.